Article Text
Abstract
Next-generation sequencing is increasingly used in clinical practice for the diagnosis of Mendelian diseases. Because of the high likelihood of secondary findings associated with this technique, the process of informing patients is beset with new challenges. One of them is regarding the type of secondary findings that ought to be disclosed to patients. The aim of this research is to propose a practical implementation of the notion of actionability, a common criteria justifying the disclosure of secondary findings but whose interpretation varies greatly among professionals. We distinguish three types of actionability corresponding to (1) well-established medical actions, (2) patient-initiated health-related actions and (3) life-plan decisions. We argue that actionability depends on the characteristics of the mutation or gene and on the values of patients. In discussing the return of secondary findings, it is important that the physician tries to get an impression of the specific situation and values of patients. Regarding variants of uncertain clinical significance in actionable genes, we found that different understandings of autonomy lead to different conclusions and that, for some of them, it may be legitimate to refrain from returning uncertain information.
- Genetic Information
- Autonomy
- Informed Consent
Statistics from Altmetric.com
Footnotes
Contributors CM wrote the first draft. All authors had full access to all the sources in this study and participated in the conception and design of the study, analysis and interpretation of the sources and revision of the manuscript for important intellectual content. All authors approved the final version.
Funding This work was supported by grants from the Käthe-Zingg-Schwichtenberg-Fonds of the Swiss Academy for Medical Sciences and from the Schmidheiny Foundation.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Diagnosing childhood - onset inborn errors of metabolism by next - generation sequencing
- Diagnostic value of targeted next - generation sequencing in patients with suspected pancreatic or periampullary cancer
- TargetPlex FFPE - Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study
- Next generation sequencing and a new era of medicine
- Practice guideline: joint CCMG - SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada
- Targeted next - generation sequencing of FNA - derived DNA in pancreatic cancer
- Evaluation of KRAS, NRAS and BRAF mutational status and microsatellite instability in early colorectal carcinomas invading the submucosa (pT1): towards an in-house molecular prognostication for pathologists
- Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next - generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice
- Implementing NGS - based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real - life experience within the framework of expert recommendations
- Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm